Navigation Links
Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Date:9/4/2007

MIAMI LAKES, Fla., Sept. 4 /PRNewswire/ -- In an extensive analysis of clinical trials known as a meta-analysis, the CYPHER(R) Sirolimus-eluting Coronary Stent was associated with significantly lower risks of blood clots and the need for reintervention compared to the Taxus Stent out to 30 months after an angioplasty procedure. This meta-analysis of 16 randomized clinical trials and 8,695 patients, the largest analysis of its kind to date, is now posted on the Journal of the American College of Cardiology website and is expected in print later in the year.

"Over the past year, concerns have been raised regarding the long-term safety of all drug-eluting stents," said Professor Albert Schomig, M.D., from Deutsches Herzzentrum, Technische Universitat in Munich, Germany, one of the authors of the study. "In this meta-analysis of randomized controlled trials, the CYPHER(R) Stent was associated with a significant reduction in the risks of stent thrombosis and reintervention compared to the Taxus Stent. This reinforces the notion that there are marked differences between the CYPHER(R) Stent and the Taxus Stent and that the safety of these drug-eluting stents must be assessed separately."

Professor Schomig added, "We find these data compelling because they are consistent with other documented meta-analyses and reflect data from all of the randomized clinical trials directly comparing these drug-eluting stents. Meta-analyses like this are an important and well-accepted statistical method among clinicians worldwide for documenting similarities and differences between two treatment modalities. We understand and appreciate that such studies are open to various interpretations by researchers and clinicians."

The primary safety endpoint of the meta-analysis was protocol-defined stent thrombosis while the secondary safety endpoints were death and heart attack (myocardial infarction or MI). The primary efficacy endpoint was the need for reintervention (targ
'/>"/>

SOURCE Cordis Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 The Wolf Administration today ... Pennsylvania State Police and local ... naloxone. Heroin and opioid overdose are the ... , killing more individuals than those involved in ... died from a drug overdose. " ...
(Date:8/31/2015)... Aug. 31, 2015  Regulatory affairs professionals work ... regulations are often strict and legislation is ever-changing. ... demand for professionals who have a deep understanding ... a product lifecycle and demonstrate its use across ... of California, Irvine Extension , in partnership with ...
(Date:8/31/2015)... Mich. , Aug. 31, 2015  Diplomat Pharmacy, Inc. ... has announced that Phil Hagerman , Chairman & CEO, ... upcoming investor conferences. Mr. Hagerman and Mr. ... Healthcare Conference in Boston on Wednesday, ... Hagerman and Mr. Whelan are also scheduled to participate in ...
Breaking Medicine Technology:Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Diplomat to Participate in Upcoming Investor Conferences 2
... May 16, 2011 Science, public health, and regulatory ... Administration. Information in this document is designed for credentialed journalists. ... 16, 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... regulatory or enforcement actions due to legal limitations. ...
... (Nasdaq: PRGO ; TASE) today announced that it ... Administration for its abbreviated new drug application for over-the-counter (OTC) ... Zantac 150®. We expect to launch early in our fiscal ... relief of heartburn associated with acid indigestion and sour stomach ...
Cached Medicine Technology:FDA News & Notes - Week of May 16, 2011 2FDA News & Notes - Week of May 16, 2011 3Perrigo Announces FDA Final Approval for Ranitidine 150 - Generic Equivalent to Zantac 150® 2
(Date:8/31/2015)... Chicago, IL (PRWEB) , ... August 31, 2015 ... ... is proud to announce a collaboration with Bright Pink® to raise money and ... Factory will donate $0.25 for each Hot Pink Sassy incandescent Mood-lite sold to ...
(Date:8/31/2015)... ... 31, 2015 , ... There’s big news for ZendyHealth , a Los ... , Consumer driven health plans (CDHPs) are a growing phenomenon, and ZendyHealth has brought ... the company, and another to answer customers’ questions directly. , John Young, CEO of ...
(Date:8/31/2015)... ... August 31, 2015 , ... Juvent Sports ( http://www.juvent.com ) just ... sports figures who are finding joint pain relief after using their revolutionary Micro-Impact Platform™ ... player in the world said, “For the first time in over 20 years I ...
(Date:8/31/2015)... , ... August 31, 2015 ... ... security executive networking and relationship-marketing firm, announced today the nominees vying for ... the Northeast U.S. Region. Executives include top-ranking decision makers representing national to ...
(Date:8/31/2015)... ... August 31, 2015 , ... Now here’s some good health news: Nearly ... least half your grains whole,” with the majority of Americans eating more whole grains ... Council (WGC) released these findings and others from the 2015 Whole Grains Consumer ...
Breaking Medicine News(10 mins):Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 3Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 3Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 2Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 3Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 4Health News:Most Americans Now Make Half Their Grains Whole 2Health News:Most Americans Now Make Half Their Grains Whole 3Health News:Most Americans Now Make Half Their Grains Whole 4Health News:Most Americans Now Make Half Their Grains Whole 5
... A study conducted recently has concluded that monitoring fetal oxygen ... the new born may be more healthier or decrease the ... part of fetal monitoring, during labor, it has been a ... levels of the unborn fetus .This is done in the ...
... anti-clotting drug called bivalirudin (Angiomax) that beats the standard ... such as heart// attacks. This new blood thinner seems ... coronary syndromes. ,The Results of the ‘Acute ... published in November issue of the New England Journal ...
... research by China-Hong Kong experts concluded that there is a ... that SARS is transmitted to human beings through// civet cats. ... on Thursday. ,The research that was carried ... Control and Protection in Beijing and Guangzhou, in cooperation with ...
... Nestlé has decided to pump in funds to the tune ... the Federal Institute of Technology in Lausanne to invest in ... power of the brain. ,The joint venture, envisaged ... children. Also research to lessen the impact of brain degenerative ...
... spiral with 4.3 million new infections //reported in 2006, with ... states a new UNAIDS report. ,The UNAIDS/WHO 2006 AIDS ... million people are living with HIV. Of these, about 8.6 ... newly infected in the past year. ,India is ...
... nearly three fourth of hospitals in Canada may not be ... therapy to prostate cancer patients. ,As a reaction ... heavily on so-called benchmarks and targets set to achieve healthcare ... in the air. To achieve the targets, it is important ...
Cached Medicine News:Health News:Fetal Oxygen Monitors Not Helpful To Prevent Mishaps In Labor:Says Study 2Health News:New Anti-Clotting Drug Less Risky For Heart Attack Patients 2Health News:More then Four Million New HIV Infections in 2006: UNAIDS 2
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
New!...
Medicine Products: